Source Report
Research Question
Research Jacob DeWitte's and Caroline Cochran's technical and operational backgrounds, their track record at Oklo prior to going public, and the governance structure established post-SPAC. Specifically examine: Sam Altman's board role, voting control dynamics, any related-party transaction disclosures, lockup expiration schedules, and insider selling patterns. Also assess the SPAC merger terms (AltC Acquisition Corp), any redemption rates, and whether the SPAC structure introduced structural overhang risks common to de-SPAC companies.
Founders' Technical and Operational Expertise
Jacob DeWitte and Caroline Cochran (now DeWitte) built Oklo's foundation through hands-on nuclear engineering: DeWitte led core designs like GE's PRISM sodium fast reactor and Sandia irradiation tests, while Cochran contributed policy and operational strategy from DoD and DOE roles, enabling the duo to pioneer a fast-fission microreactor using recycled fuel that avoids high-pressure water systems for simpler, safer deployment.[1][2][3]
- DeWitte: BS Nuclear Engineering (Florida), SM/PhD MIT; prior at GE (PRISM core), Sandia (fast test reactor), Urenco, Naval Reactors.[4]
- Cochran: BS Mechanical Eng/BA Economics (Oklahoma), SM Nuclear MIT; DoD policy, DOE Advisory Committee; operationalized Oklo's Licensing Modernization Project pilot with NRC.
- Pre-public: Founded 2013 post-MIT; won MIT $100K (2013), YC (2014); first advanced reactor COLA (2020, denied w/o prejudice for info gaps amid COVID); secured INL site/fuel (2020), NRC QA/Safeguards approvals; team grew to 51 (16% PhDs) with ex-NRC hires.[6][7]
Implication for competitors: Their data moat from 10+ years of NRC engagement (70+ meetings, 50 docs) and fuel recycling IP creates a licensing lead; entrants need equivalent expertise or risk 2-3 year delays, as seen in Oklo's 2020 setback.
Pre-Public Track Record at Oklo
DeWitte/Cochran advanced from concept to DOE site permit by iterating reactor designs on proven sodium fast tech (EBR-II heritage), submitting novel COLA amid pandemic, and pivoting post-denial to hybrid DOE/NRC path for 2027 Aurora-INL demo—progressing fuel fab SDS approval (2024) without revenue but with $50M+ raised privately.[8][7]
- 2013: Founded post-MIT; YC 2014 (Altman recruit).
- Milestones: INL fuel/site (2020); first COLA (Mar 2020, denied 2022 w/o prejudice); NRC QA/Safeguards OK; 15+ pre-app meetings (2022+).
- Funding: ~$50M private (Altman lead 2015); no revenue, but pipeline: Equinix LOI (2024, $25M prepay ROFR), data center MOU.
- Team: 51 employees (39% MS/PhD); 6 ex-NRC.
Implication for competitors: Proved regulatory persistence yields fuel/site edges (5MT EBR-II recycled); rivals without similar history face higher failure risk on novel licensing.
SPAC Merger with AltC Acquisition Corp.
AltC (Altman/Klein SPAC, $500M IPO 2021) merged May 9, 2024 at $850M pre-money equity value via all-stock exchange (100% Oklo rollover, no cashout), delivering $306M gross proceeds post-low redemptions (~39% vs. SPAC avg 90%+), but debut pop faded to -54% Day 1 on pre-revenue overhang—mechanism preserved cash for 2027 demo while diluting via 6.06x ratio.[9][10][11]
- Terms: $850M equity value ($10/sh); 15M earnout shares (3 tranches: $12/$15/$20+ for 20/60 days, 5yrs; triggered Nov 2024).[12]
- Redemptions: Low (~710 shares min cash condition met); trust ~$500M → $306M net.
- Pro forma: Oklo holders ~67% (no-redemp assume).
Implication for competitors: Low redemptions rare for de-SPACs (beats 2023 avg 95%), funding runway sans dilution; pure-play nuclear SPACs face higher redemption drag.
Post-SPAC Governance and Sam Altman's Role
Post-merger board blended Oklo founders (DeWitte CEO/Chair post-Altman, Cochran COO/Director) with independents (Klein, Poneman, etc.), single-class shares (equal vote), Altman as initial Chair (recused merger review) until Apr 2025 resignation for OpenAI conflict—mechanism aligned incentives via committees (ex-NRC on audit/comp).[13][14]
- Board: DeWitte (Chair), Cochran, Klein, Poneman, Thompson, Kinzley (ACFE), Jansen (Ret. Gen).
- Altman: Chair 2015-2025 (2.58% post-SPAC); recused AltC/Oklo boards pre-deal; no voting control.
- No dual-class; standard committees.
Implication for competitors: Founder-led + independents/ex-regulators accelerates NRC path; Altman's exit enables AI deals (e.g., OpenAI), rivals lack such networks.
Voting Control, Related-Party Transactions, and Lockups
Founders retained ~18% post-SPAC (DeWitte 13M/9%, Cochran 12.9M/9% at $0.0001 avg cost), no super-voting but 62% pre-vote support via agreement; staggered 3yr lockups (founders/sponsor) + performance-vest sponsor shares ($10/$12/$14-16) mitigated overhang, triggered Nov 2024—no major RPTs beyond Altman investment/Sponsor support.[12][13][6]
- Voting: Single-class; founders ~18% stake, no control block.
- RPTs: Altman (early investor/Chair); Sponsor private shares; Equinix $25M prepay LOI (non-refundable discount).[15]
- Lockups: 180-day standard (exp Nov 2024); staggered 3yr founders/sponsor; sponsor vest 50% Nov 2024 ($10 hit).[16]
Implication for competitors: Vesting/lockups aligned long-term; low dilution vs. peers, but post-exp sales signal liquidity needs.
Insider Selling and De-SPAC Overhang Risks
Post-lockup (Nov 2024), patterned sales via 10b5-1 plans (DeWitte/Cochran ~$100M+ 2025-26 at $60-80/sh, CFO $5M+) reflect diversification amid no revenue/2027 commercialization, amplifying de-SPAC overhang: low float post-redemptions + earnout dilution (15M issued Nov 2024) pressured stock -54% debut despite $306M cash.[17][18][10]
- Selling: Founders 1.2M+ sh (2025-26); total insiders ~2M sh $164M last 3mo (2026).
- Risks: 51% float resale-eligible; execution/reg delays burn cash ($40-50M/yr op loss); SPAC stigma (volatility, scrutiny).
Implication for competitors: Overhang caps multiples pre-revenue; entrants via traditional IPO avoid but miss SPAC speed/cash—tradeoff favors nuclear's long timelines.
Recent Findings Supplement (March 2026)
Leadership Continuity with Strategic Board Shift
Jacob DeWitte and Caroline Cochran remain CEO/Chairman and COO respectively, leveraging their MIT nuclear engineering backgrounds and 20/15 years of experience to advance projects like the Aurora-INL powerhouse groundbreaking in September 2025; DeWitte assumed Chairman role post-Altman's April 2025 resignation to avoid OpenAI conflicts, enabling broader AI energy deals without perceived bias.[1][2]
- DeWitte/Cochran founded Oklo in 2013 at MIT; pre-public track record includes 2020 NRC application denial (resolved via redesign), DOE site permit/fuel award by 2024, and 2025 Atomic Alchemy acquisition for radioisotopes.[3]
- Altman retains ~3.15M shares via Hydrazine Capital but no board seat; Energy Sec. Chris Wright (former board member) recused from Oklo decisions amid scrutiny.[4]
For competitors: Founders' hands-on nuclear ops experience creates execution moat; replicate via DOE/national lab partnerships, but post-SPAC talent retention key.
SPAC Merger Legacy: Low Redemption Clears Overhang
AltC delivered $306M gross proceeds at May 2024 close (<0.01% final redemptions after 44.4% extension vote), funding 2025 milestones without dilution overhang; founder/earnout shares (12.5M/15M) fully vested Nov 2024 on price triggers, eliminating contingent issuance risks typical in de-SPACs.[3][5]
- Net proceeds post-fees: $259M; no major overhang as SPAC cash nearly intact vs. peers' 80-90% redemptions.
- 2025 Q3 cash: $1.184B (post-$526M ATM), supports runway sans further SPAC drag.
Entrants: Target SPACs with committed sponsors like AltC (Klein/Altman) for low-redemption outcomes; overhang fades post-earnout vesting.
Governance: Founder-Led with Post-SPAC Stability
Post-merger board (DeWitte Chairman/CEO, Cochran COO, independents) emphasizes nuclear expertise; no 2025-26 proxy (DEF 14A April 2025 confirmed Altman exit); Item 13 disclosures note Atomic Alchemy acquisition (Feb 2025: $1M cash + 1.1M shares, some vesting/lockup) as key related-party but no ongoing conflicts or voting superpowers.[3]
- Voting: Standard one-share-one-vote; founders retain influence via ~10%+ stakes (post-sales).
- No new policy/regulatory shifts; Q3 2025 10-Q flags human capital risks but stable leadership.
Competitors: Founder control aids agility but invites scrutiny; diversify board for institutional trust.
Insider Activity: Planned Sales Signal Liquidity, Not Distress
DeWitte/Cochran executed 10b5-1 sales (adopted Mar 2025): ~340K shares (~$21M) Mar 2 2026 at $60-64; prior clusters (Sep 2025: $3M DeWitte gift; Dec 2025: 7.9M to trusts); total 2025-26 sales ~$152M+ but holdings remain substantial (DeWitte: 679K direct post-sale).[6][7]
- Form 144/4 patterns: Routine diversification post-vesting/ATM highs; no Altman sales noted.
- Lockups: Atomic shares vested; SPAC-era expired ~Nov 2024 (post-earnout).
New entrants: Use 10b5-1 early to preempt optics; monitor for volume spikes signaling weakness.
Recent Momentum: Fuel/Regulatory Wins Offset Cash Burn
Q3 2025 net loss $29.7M ($0.20/share), ops cash $48.7M YTD (in FY guide); $1.2B liquidity funds Aurora-INL (groundbreak Sep 2025), Atomic pilot (criticality Jul 2026), Meta 1.2GW Ohio deal (Jan 2026), Centrus JV (Mar 2026 HALEU deconversion).[8][9]
- DOE RPP awards (3/11 projects) accelerate timelines vs. NRC; fuel from EBR-II/plutonium bridges HALEU.
Rivals: Oklo's integrated fuel/recycling + AI hyperscaler PPAs (Meta post-Altman exit) de-risks; compete via similar DOE paths but pre-revenue burn (~$70M/yr) demands flawless execution.